Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F97J4
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $27,368
Award facts
- Contract value 100% obligated
- $27,367.65 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $27,367.65 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on January 20, 2026, with completion scheduled for January 21, 2026. This firm fixed-price contract, which carries no set-aside designation, represents a competitive award to the pharmaceutical distributor's Conshohocken, Pennsylvania location. The delivery order is issued under AmerisourceBergen Drug Corp's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, a single-award IDC valued at up to $999.99 million through December 31, 2031, which serves as the primary vehicle for supplying comprehensive pharmaceutical products and medical supplies to military healthcare programs globally.
AmerisourceBergen, operating as a subsidiary of Cencora, Inc., is a major pharmaceutical distributor and critical federal vendor specializing in delivering brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to military and veteran healthcare systems. The Dupixent supply under this delivery order supports the Defense Logistics Agency's medical supply chain operations, providing an immunosuppressant medication commonly used in dermatological and allergic disease treatment. This award demonstrates the company's continued capability to meet federal procurement requirements through open competition and its established role as a key supplier within the broader pharmaceutical support infrastructure serving Department of Defense healthcare programs.
Quick answers
Who was awarded contract SPE2DR26F97J4?
SPE2DR26F97J4 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26F97J4 worth?
The government has obligated $27,368 on SPE2DR26F97J4.
Is contract SPE2DR26F97J4 an order under another contract?
Yes. SPE2DR26F97J4 is a delivery order under SPE2DR25D3505, an indefinite delivery contract.
Was contract SPE2DR26F97J4 competed?
The extent of competition for SPE2DR26F97J4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award